{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:05:58Z","timestamp":1792436758511,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013590","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000}}],"reference-count":176,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013590.pub2","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:00:36Z","timestamp":1716361236000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antioxidant supplementation for sickle cell disease"],"prefix":"10.1002","volume":"2024","author":[{"given":"Abiola B","family":"Bolarinwa","sequence":"additional","affiliation":[{"name":"Department of Haematology & Blood Transfusion Medicine; Lagos University Teaching Hospital; Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabisi","family":"Oduwole","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science; Achievers University; Owo Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Okebe","sequence":"additional","affiliation":[{"name":"Department of International Public Health; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A","family":"Ogbenna","sequence":"additional","affiliation":[{"name":"Department of Haematology & Blood Transfusion Medicine; College of Medicine, University of Lagos; Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi E","family":"Otokiti","sequence":"additional","affiliation":[{"name":"Department of Haematology & Blood Transfusion Medicine; Lagos University Teaching Hospital; Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adejoke T","family":"Olatinwo","sequence":"additional","affiliation":[{"name":"Department of Haematology & Blood Transfusion Medicine; Lagos University Teaching Hospital; Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12185","article-title":"Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial","volume":"160","author":"Arruda","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD013590.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V108.11.1203.1203","article-title":"Beneficial effect of zinc supplementation on oxidative stress, cytokines and NF-KB DNA binding in sickle cell disease patients","volume":"108","author":"Bao","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.trsl.2008.06.001","article-title":"Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients","volume":"152","author":"Bao","year":"2008","journal-title":"Translational Research"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MPH.0000000000001673","article-title":"Effect of high-dose vitamin a supplementation in children with sickle cell disease: a randomized, double-blind, dose-finding pilot study","volume":"42","author":"Brownell","year":"2020","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0005|cit5","unstructured":"Nutritional outcomes after vitamin A supplementation in subjects with SCD clinicaltrials.gov\/ct2\/show\/NCT03632876"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bcmd.2015.03.014","article-title":"Omega 3 (n\u2212 3) fatty acids down-regulate nuclear factor-kappa B (NF-\u03baB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease","volume":"55","author":"Daak","year":"2015","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3945\/ajcn.112.036319","article-title":"Effect of omega-3 (n\u2212 3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial","volume":"97","author":"Daak","year":"2013","journal-title":"American Journal of Clinical Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.plefa.2013.09.006","article-title":"Docosahexaenoic and eicosapentaenoic acid supplementation does not exacerbate oxidative stress or intravascular haemolysis in homozygous sickle cell patients","volume":"89","author":"Daak","year":"2013","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0009|cit9","first-page":"S8","article-title":"Clinical effect of SC411 (Altemia TM) on children with sickle cell disease in the scot trial: a phase 2 randomized, double-blind, placebo-controlled, parallel-group, dose-finding multi-center study","volume":"65","author":"Daak","year":"2018","journal-title":"Pediatric Blood & Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0010|cit10","first-page":"S122","article-title":"Effects of SC411 (altemiatm) on blood cell membrane omega-3 index and select sickle cell disease biomarkers in the scot trial: a phase 2 randomized, doubleblind, placebo-controlled, parallel-group, multi-center study","volume":"65","author":"Daak","year":"2018","journal-title":"Pediatric Blood & Cancer"},{"issue":"15","key":"10.1002\/14651858.CD013590.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Advances"},{"issue":"4","key":"10.1002\/14651858.CD013590.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3945\/ajcn.112.035725","article-title":"No improvement in suboptimal vitamin A status with a randomized, double-blind, placebo-controlled trial of vitamin A supplementation in children with sickle cell disease","volume":"96","author":"Dougherty","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"4397150","DOI":"10.1155\/2019\/4397150","article-title":"Double-blind clinical trial of arginine supplementation in the treatment of adult patients with sickle cell anaemia","volume":"2019","author":"Eleuterio","year":"2019","journal-title":"Advances in Hematology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Fung E Kawchak D Zemel B Ohene-Frempong K Stallings V Plasma zinc is not a sensitive indicator of zinc status in children with sickle cell disease National Sickle Cell Disease Program Annual Meeting Conference Proceedings; 2001 April; New York (NY) 2001","DOI":"10.1177\/0115426502017006365"},{"issue":"6","key":"10.1002\/14651858.CD013590.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0115426502017006365","article-title":"Plasma zinc is an insensitive predictor of zinc status: use of plasma zinc in children with sickle cell disease","volume":"17","author":"Fung","year":"2002","journal-title":"Nutrition in Clinical Practice"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0016|cit16","unstructured":"Zemel B Kawchak D Fung E Ohene-Frempong K Stallings V Zinc supplementation and linear growth in children with sickle cell disease: a pilot study National Sickle Cell Disease Program Annual Meeting Conference Proceedings; November 10-12, 2001 Sedona, Arizona, USA the National Sickle Cell Disease Program"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/75.2.300","article-title":"Effect of zinc supplementation on growth and body composition in children with sickle cell disease","volume":"75","author":"Zemel","year":"2002","journal-title":"American Journal of Clinical Nutrition"},{"issue":"7","key":"10.1002\/14651858.CD013590.pub2-BIB0018|cit18","first-page":"467","article-title":"Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial","volume":"43","author":"Gupta","year":"1995","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0019|cit19","unstructured":"Koshy M Askin M McMahon L Adams-Graves P Halloway L Faller DV Arginine butyrate in sickle cell leg ulcers: interim findings of a phase II trial National Sickle Cell Disease Program 24th Annual Meeting; 2000 April New Orleans, Louisiana, USA. American Society of Hematology 4 1 st Anriual Meeting ,December 3-7, 1999 2000 175a"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0020|cit20","unstructured":"Koshy M Askin M McMahon L Adams-Graves P Halloway L Faller DV Arginine butyrate in sickle cell leg ulcers: interim findings of a randomized phase II trial National Sickle Cell Disease Program 25th Annual meeting; 2001 April; New York (NY) 2001"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0021|cit21","first-page":"417a","article-title":"Arginine butyrate in sickle cell leg ulcers: interim findings of a phase II trial","volume":"94","author":"Koshy","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clnu.2009.01.017","article-title":"Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients","volume":"28","author":"Martins","year":"2009","journal-title":"Clinical Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2010.08395.x","article-title":"A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers","volume":"151","author":"McMahon","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"11 Pt 1 of 2","key":"10.1002\/14651858.CD013590.pub2-BIB0024|cit24","first-page":"10a","article-title":"A phase II trial of arginine butyrate in refractory sickle cell leg ulcers","volume":"100","author":"McMahon","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0025|cit25","unstructured":"Phase II randomized trial: arginine butyrate plus standard local therapy in patients with refractory sickle cell ulcers clinicaltrials.gov\/show\/NCT00004412"},{"issue":"22","key":"10.1002\/14651858.CD013590.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood.V114.22.573.573","article-title":"Arginine therapy for vaso-occlusive pain episodes in sickle cell disease","volume":"114","author":"Morris","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD013590.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2019-122983","article-title":"Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: a randomized placebo-controlled trial in progress","volume":"134","author":"Morris","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2018-99-117529","article-title":"Consistent compliance with hydroxyurea and hematology measures during L-glutamine therapy for sickle cell anemia","volume":"132","author":"Gordeuk","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2021-154477","article-title":"The evaluation of transfusion data from the phase 3 clinical study of L-glutamine in sickle cell disease","volume":"138","author":"Lam","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0031|cit31","unstructured":"A phase III safety and efficacy study of l-glutamine to treat sickle cell disease or sickle \u03b2o-thalassemia clinicaltrials.gov\/show\/NCT01179217"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V130.Suppl_1.685.685","article-title":"Phase 3 study of l-glutamine in sickle cell disease: analyses of time to first and second crisis and average cumulative recurrent events","volume":"130","author":"Niihara","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2018-99-119720","article-title":"Consistent benefit of L-glutamine observed across patients with low, medium, and high number of crises reported in the year prior to screening-analysis from the phase 3 study of L-glutamine in sickle cell anemia","volume":"132","author":"Niihara","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD013590.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.V126.23.2175.2175","article-title":"Decrease in the severity of painful sickle cell crises with oral PGLG","volume":"126","author":"Niihara","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD013590.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.V128.22.1318.1318","article-title":"Phase 3 study of l-glutamine therapy in sickle cell anemia and sickle beta0 -thalassemia subgroup analyses show consistent clinical improvement","volume":"128","author":"Niihara","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.V128.22.1318.1318","article-title":"Phase 3 study of l-glutamine therapy in sickle cell anemia and sickle beta0-thalassemia subgroup analyses show consistent clinical improvement","volume":"128","author":"Niihara","year":"2016","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013590.pub2-BIB0038|cit38","first-page":"719","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients","volume":"92","author":"Nur","year":"2010","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00277-011-1404-z","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients","volume":"91","author":"Nur","year":"2012","journal-title":"Annals of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1164\/rccm.202108-1930OC","article-title":"Arginine therapy and cardiopulmonary hemodynamics in hospitalized children with sickle cell anemia: a prospective, double-blinded, randomized placebo-controlled clinical trial","volume":"206","author":"Onalo","year":"2022","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood-2019-122510","article-title":"Oral arginine therapy as a novel adjuvant in the management of acute pain in children with sickle cell anemia in Nigeria: a randomized placebo-controlled trial","volume":"134","author":"Onalo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.26028","article-title":"Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria","volume":"96","author":"Onalo","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-134123","article-title":"Impact of oral arginine therapy on global arginine bioavailability in Nigerian children sickle cell anemia and vaso-occlusive pain","volume":"136","author":"Onalo","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0045|cit45","first-page":"246","article-title":"Zinc in sickle cell disease","volume":"96","author":"Prasad","year":"1983","journal-title":"Transactions of the Association of American Physicians"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Prasad AS Cossack ZT Zinc supplementation and growth in sickle cell disease Annals of Internal Medicine 1984 100 3 367 71","DOI":"10.7326\/0003-4819-100-3-367"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0047|cit47","first-page":"49","article-title":"Zinc deficiency in sickle cell disease","volume":"165","author":"Prasad","year":"1984","journal-title":"Progress in Clinical and Biological Research"},{"issue":"4","key":"10.1002\/14651858.CD013590.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2141.1983.tb02138.x","article-title":"A trial of folate supplementation in children with homozygous sickle cell disease","volume":"54","author":"Rabb","year":"1983","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD013590.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.amjcard.2013.06.035","article-title":"Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels","volume":"112","author":"Scoffone","year":"2013","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Serjeant GR Galloway RE Gueri MC Oral zinc sulphate in sickle-cell ulcers Lancet 1970 2 7679 891 2 4097279","DOI":"10.1016\/S0140-6736(70)92067-2"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0190-9622(97)70156-7","article-title":"Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study","volume":"37","author":"Serjeant","year":"1997","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"22","key":"10.1002\/14651858.CD013590.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V128.22.123.123","article-title":"N-acetylcysteine in patients with sickle cell disease: a randomized controlled trial","volume":"128","author":"Sins","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0053|cit53","first-page":"2244","article-title":"Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial","volume":"130","author":"Sins","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.14809","article-title":"Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial","volume":"182","author":"Sins","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0055|cit55","first-page":"2244","article-title":"Effects of oral N-acetylcysteine on oxidative stress in patients with sickle cell disease","volume":"130","author":"Sins","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0056|cit56","unstructured":"Fabry ME Romero JR Rivera A Styles L Kesler K Reiss UM Characterization of hyperdense cells in a pediatric cohort of sickle cell disease patients-results of the CSCC multi-institution study of arginine supplementation 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA 2007 280"},{"issue":"11","key":"10.1002\/14651858.CD013590.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V110.11.2252.2252","article-title":"Arginine therapy does not benefit children with sickle cell anemia - results of the CSCC clinical trial consortium multi-institutional study","volume":"110","author":"Styles","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0058|cit58","unstructured":"Styles L Kuypers F Kesler K Reiss U Lebeau P Nagel R Arginine therapy does not benefit children with sickle cell anemia- results of the cscc multi-center 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA Washington DC, USA 2007 194"},{"issue":"10 Suppl 1 (Pt","key":"10.1002\/14651858.CD013590.pub2-BIB0059|cit59","first-page":"445a","article-title":"Dietary n-3 fatty acid treatment reduces the frequency of pain episodes and the prothrombic state in sickle cell disease","volume":"90","author":"Tomer","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0060|cit60","first-page":"299a","article-title":"Reduced predisposition to thrombosis in sickle cell disease (SCD) patients treated with dietary n-3 fatty acids (n-3FA)","volume":"86","author":"Tomer","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD013590.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1055\/s-0037-1615948","article-title":"Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids","volume":"85","author":"Tomer","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD013590.pub2-BIB0062|cit62","first-page":"418","article-title":"Clinical trial of riboflavin in sickle cell disease","volume":"70","author":"Ajayi","year":"1993","journal-title":"East African Medical Journal"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0063|cit63","unstructured":"Eberhardt RT McMahon L Steinberg MH Perrine SP Denson C Vita JA Effect of vitamin C and L-arginine on vascular function in sickle cell disease National Sickle Cell Disease Program 30th Annual Meeting Conference Proceedings; 2002 Sept 17-21 2002 199"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.12114","article-title":"L-arginine as an adjuvant drug in the treatment of sickle cell anaemia","volume":"160","author":"Elias","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1179\/1607845413Y.0000000099","article-title":"Effect of zinc supplementation on serum antibody titers to heat shock protein 27 in patients with thalassemia major","volume":"19","author":"Ghahramanlu","year":"2014","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2018-99-117529","article-title":"Consistent compliance with hydroxyurea and hematology measures during L-glutamine therapy for sickle cell anemia","volume":"132","author":"Gordeuk","year":"2018","journal-title":"Blood"},{"issue":"19","key":"10.1002\/14651858.CD013590.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMc1811050","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Guddati","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"366\u201370","DOI":"10.1093\/tropej\/48.6.366","article-title":"Blood pressure, hematologic and erythrocytefragility changes in children suffering from sicklecell anemia following ascorbic acid supplementation","volume":"48","author":"Jaja","year":"2002","journal-title":"Journal of Tropical Pediatrics"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.niox.2017.12.009","article-title":"A pilot study of a non-invasive oral nitrate stable isotopic method suggests that arginine and citrulline supplementation increases whole-body NO production in Tanzanian children with sickle cell disease","volume":"74","author":"Marealle","year":"2018","journal-title":"Nitric Oxide"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Mirhosseini NN Ghayour-Mobarhan M Shasar S Mohdyusoff NA Banihashem A Kamarudin AN The effect of zinc supplementation on growth and bone health in Iranian paediatric patients with transfusion-dependent beta thalassemia Clinical Biochemistry 2011 44 13 Suppl 1 S18 9","DOI":"10.1016\/j.clinbiochem.2011.08.054"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0071|cit71","unstructured":"Trial of oral glutamine in patients with sickle cell anemia clinicaltrials.gov\/show\/NCT00131508"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<194::AID-AJH6>3.0.CO;2-C","article-title":"Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)","volume":"61","author":"Prasad","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<194::AID-AJH6>3.0.CO;2-C","article-title":"Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)","volume":"61","author":"Prasad","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013590.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2018-99-112666","article-title":"Parenteral L-arginine improves mitochondrial function in children with sickle cell disease admitted for vaso-occlusive pain episodes","volume":"132","author":"Shiva","year":"2018","journal-title":"Blood"},{"issue":"42","key":"10.1002\/14651858.CD013590.pub2-BIB0075|cit75","first-page":"1573","article-title":"Tolerance of large doses of oral zinc sulfate","volume":"111","author":"Tschumi","year":"1981","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"14","key":"10.1002\/14651858.CD013590.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.26355\/eurrev_202207_29290","article-title":"Comparative effectiveness of adding omega-3 or vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients","volume":"26","author":"Abdelhalim","year":"2022","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD013590.pub2-BIB0077|cit77","first-page":"683","article-title":"Ascorbic acid in sickle cell disease: results of a pilot therapeutic trial","volume":"60","author":"Akinkugbe","year":"1983","journal-title":"East African Medical Journal"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0078|cit78","first-page":"241","article-title":"The use of pharmacological doses of zinc in the treatment of sickle cell anemia","volume":"14","author":"Brewer","year":"1977","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0079|cit79","first-page":"618","article-title":"L-arginine supplementation decreases hemolysis and pulmonary arterial hypertension in sickle cell disease patients: a randomized, double-blinded, placebo-controlled trial","volume":"101 Suppl 1","author":"Friedrisch","year":"2016","journal-title":"Haematologica"},{"issue":"5A","key":"10.1002\/14651858.CD013590.pub2-BIB0080|cit80","first-page":"477","article-title":"RBC survival, zinc deficiency, and efficacy of zinc therapy in sickle cell disease","volume":"23","author":"Gupta","year":"1987","journal-title":"Birth Defects Original Article Series"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0081|cit81","first-page":"803","article-title":"Efficacy of oral zinc therapy in the management of sickle cell crises","volume":"86","author":"Gupta","year":"1987","journal-title":"Indian Journal of Medical Research"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0082|cit82","unstructured":"Koh H Sungar M Macan H Johnson C Tanaka K Niihara Y Prospective randomized crossover double-blind trial of L-glutamine for the therapy of sickle cell disease National Sickle Cell Disease Program 28 Annual Meeting; 2005 April 9-13; Cincinnati, Ohio 2005 146"},{"issue":"13","key":"10.1002\/14651858.CD013590.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1182\/bloodadvances.2022008539","article-title":"Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial","volume":"7","author":"Namazzi","year":"2023","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0084|cit84","unstructured":"Effectiveness of arginine as a treatment for sickle cell anemia (Arginine) clinicaltrials.gov\/study\/NCT00513617"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0085|cit85","unstructured":"L-glutamine therapy for sickle cell anemia clinicaltrials.gov\/study\/NCT00586209"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0086|cit86","unstructured":"Antioxidant therapy to reduce inflammation in sickle cell disease clinicaltrials.gov\/ct2\/show\/NCT01054768"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0087|cit87","unstructured":"N-acetylcysteine in patients with sickle cell disease clinicaltrials.gov\/show\/NCT01849016"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0088|cit88","unstructured":"Zinc supplementation in children with sickle cell disease in Western Kenya clinicaltrials.gov\/ct2\/show\/NCT03293641"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0089|cit89","unstructured":"Pharmacokinetics and safety of endari (L-glutamine) in sickle cell disease patients clinicalTrials.gov\/show\/NCT04684381"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0090|cit90","unstructured":"Glutamine role in preventing vaso-occlusive crisis among SCD patients (Glu_SCD_Egy) clinicaltrials.gov\/show\/NCT05371184"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s13063-019-3569-z","article-title":"Zinc for infection prevention in sickle cell anemia (zips): study protocol for a randomized placebo-controlled trial in ugandan children with sickle cell anemia","volume":"20","author":"Datta","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0092|cit92","unstructured":"Zinc for infection prevention in sickle cell anemia (ZIPS) (ZIPS) clinicaltrials.gov\/study\/NCT03528434"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0093|cit93","unstructured":"N-acetylcystein for sickle cell disease www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-005889-40\/NL"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0094|cit94","unstructured":"The effect of combination therapy of L-glutamine and hydroxyurea in patients with sickle cell anemia trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20210715051904N1"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0095|cit95","unstructured":"Randomized trial of LOVAZA in pediatric sickle cell disease (SCD) clinicaltrials.gov\/show\/NCT01202812"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0096|cit96","unstructured":"Efficacy of antioxidant therapy compared with enalapril in sickle nephropathy clinicaltrials.gov\/show\/NCT01891292"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0097|cit97","unstructured":"Prevention of vaso-occlusive painful crisis by using omega-3 fatty acid supplements (OM3FA) clinicaltrials.gov\/show\/nct02525107"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0098|cit98","unstructured":"Folic acid supplementation in children with sickle cell disease clinicaltrials.gov\/study\/NCT04011345"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0099|cit99","unstructured":"Different treatment modalities in the management of the painful crisis in pediatric sickle-cell anemia clinicaltrials.gov\/ct2\/show\/NCT04301336"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0100|cit100","unstructured":"Sickle cell disease treatment with arginine therapy (STArT) trial (STArT) clinicaltrials.gov\/ct2\/show\/NCT04839354"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0101|cit101","unstructured":"NAC trial www.onderzoekmetmensen.nl\/en\/trial\/28196"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0102|cit102","unstructured":"Omega-3 and vitamin D supplementation in adults with sickle cell anemia ensaiosclinicos.gov.br\/rg\/RBR-10r7d6f3"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0103|cit103","unstructured":"Folic acid supplementation in children with sickle cell disease clinicaltrials.gov\/show\/NCT04011345"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s13063-020-04540-7","article-title":"Folic acid supplementation in children with sickle cell disease: study protocol for a double-blind randomized cross-over trial","volume":"21","author":"Williams","year":"2020","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0105|cit105","first-page":"61","article-title":"Treatment of sickle cell disease - options and perspective","volume":"13","author":"Abdel-Hadi","year":"2023","journal-title":"American Journal of Blood Research"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1037696","DOI":"10.3389\/fnut.2022.1037696","article-title":"Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: a systematic review","volume":"9","author":"Amiri","year":"2022","journal-title":"Frontiers in Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/medsci7020017","article-title":"Oxidative profile of patients with sickle cell disease","volume":"7","author":"Antwi-Boasiako","year":"2019","journal-title":"Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1749-6632.2000.tb06201.x","article-title":"Reactive species in sickle cell disease","volume":"899","author":"Aslan","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"18","key":"10.1002\/14651858.CD013590.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2012-04-383430","article-title":"Sickle cell pain: a critical reappraisal","volume":"120","author":"Ballas","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD013590.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-011-1340-y","article-title":"Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time","volume":"91","author":"Belini Junior","year":"2012","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Biswas SK Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxidative Medicine and Cellular Longevity 2016 2016","DOI":"10.1155\/2016\/5698931"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/j.pain.0000000000000824","article-title":"Sickle cell disease: a natural model of acute and chronic pain","volume":"158 Suppl 1","author":"Brandow","year":"2017","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD013590.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1541-4337.2011.00156.x","article-title":"Natural antioxidants: sources, compounds, mechanisms of action, and potential applications","volume":"10","author":"Brewer","year":"2011","journal-title":"Comprehensive Reviews in Food Science and Food Safety"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1054\/mehy.2000.1310","article-title":"Sickle cell disease: a chronic inflammatory condition","volume":"57","author":"Chies","year":"2001","journal-title":"Medical Hypotheses"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/iub.584","article-title":"Role of oxidative stress in the pathogenesis of sickle cell disease","volume":"64","author":"Chirico","year":"2012","journal-title":"IUBMB Life"},{"issue":"11","key":"10.1002\/14651858.CD013590.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/phar.2329","article-title":"Systematic review of L-glutamine for prevention of vaso-occlusive pain crisis in patients with sickle cell disease","volume":"39","author":"Cieri-Hutcherson","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2-3","key":"10.1002\/14651858.CD013590.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/CH-189012","article-title":"Inflammation in sickle cell disease","volume":"68","author":"Conran","year":"2018","journal-title":"Clinical Hemorheology and Microcirculation"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0118|cit118","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0119|cit119","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/pbc.24163","article-title":"Micronutrients and sickle cell disease, effects on growth, infection and vaso-occlusive crisis: a systematic review","volume":"59","author":"Dekker","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cca.2020.07.020","article-title":"Antioxidant nutrients and hemolysis in sickle cell disease","volume":"510","author":"Delesderrier","year":"2020","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/antiox12030632","article-title":"Antioxidant and Anti-Tumor Effects of Dietary Vitamins A, C, and E","volume":"12","author":"Didier","year":"2023","journal-title":"Antioxidants"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0123|cit123","first-page":"377","article-title":"Effects of antioxidant supplementation on the aging process","volume":"2","author":"Fusco","year":"2007","journal-title":"Clinical Intervntions in Ageing"},{"issue":"10","key":"10.1002\/14651858.CD013590.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4149\/bll_2014_116","article-title":"Antioxidants in health and disease","volume":"115","author":"Ginter","year":"2014","journal-title":"Bratislavske lekarske listy (Bratislava Medical Journal)"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcmd.2011.01.002","article-title":"Assessment of oxidative stress in patients with sickle cell disease: the glutathione system and the oxidant-antioxidant status","volume":"46","author":"Gizi","year":"2011","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0126|cit126","first-page":"53","article-title":"The irreversibly sickled cell: a perspective","volume":"50","author":"Goodman","year":"2004","journal-title":"Cellular and Molecular Biology"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0127|cit127","unstructured":"GRADEpro GDT McMaster University (developed by evidence Prime) 2015"},{"issue":"6 Suppl 4","key":"10.1002\/14651858.CD013590.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: A neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"American Journal of Preventive Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"e0246700","DOI":"10.1371\/journal.pone.0246700","article-title":"Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: a systematic review of randomized controlled trials","volume":"16","author":"Gyamfi","year":"2021","journal-title":"PLoS One"},{"issue":"7414","key":"10.1002\/14651858.CD013590.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0131|cit131","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook\/PDF\/v5.2\/"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0132|cit132","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0133|cit133","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022), Cochrane Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0134|cit134","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0135|cit135","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0136|cit136","first-page":"68","article-title":"Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension","volume":"24","author":"Horiuchi","year":"1996","journal-title":"Experimental Hematology"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"014","DOI":"10.23937\/2572-3278.1510014","article-title":"Niacin and oxidative stress: a mini-review","volume":"2","author":"Ilkhani","year":"2016","journal-title":"Journal of Nutritional Medicine and Diet Care"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0006-3002(58)90516-X","article-title":"Abnormal human haemoglobins","volume":"28","author":"Ingram","year":"1958","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0139|cit139","first-page":"506","volume-title":"International Encyclopedia of Public Health","author":"Johnson","year":"2016"},{"issue":"12","key":"10.1002\/14651858.CD013590.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/s0891-5849(01)00543-3","article-title":"Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity","volume":"30","author":"Joshi","year":"2001","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12937-016-0186-5","article-title":"The importance of antioxidants which play the role in cellular response against oxidative\/nitrosative stress: current state","volume":"15","author":"Kurutas","year":"2016","journal-title":"Nutrition Journal"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0142|cit142","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jbiomech.2016.11.022","article-title":"Biomechanics and biorheology of red blood cells in sickle cell anemia","volume":"50","author":"Li","year":"2017","journal-title":"Journal of Biomechanics"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0144|cit144","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.fct.2018.03.029","article-title":"l-Arginine induces antioxidant response to prevent oxidative stress via stimulation of glutathione synthesis and activation of Nrf2 pathway","volume":"115","author":"Liang","year":"2018","journal-title":"Food and Chemical Toxicology"},{"issue":"3","key":"10.1002\/14651858.CD013590.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.24986","article-title":"The clinical epidemiology of sickle cell anemia In Africa","volume":"93","author":"Macharia","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antiox6020024","article-title":"Zinc and oxidative stress: current mechanisms","volume":"6","author":"Marreiro","year":"2017","journal-title":"Antioxidants"},{"issue":"10","key":"10.1002\/14651858.CD013590.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jnutbio.2005.05.013","article-title":"Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes","volume":"16","author":"Masella","year":"2005","journal-title":"Journal of Nutritional Biochemistry"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"12978","DOI":"10.1038\/s41598-019-49362-z","article-title":"Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages from patients with small abdominal aortic aneurysm","volume":"9","author":"Meital","year":"2019","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2007-04-081703","article-title":"Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease","volume":"111","author":"Morris","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0152|cit152","first-page":"279","volume-title":"Food Chemistry","author":"Nawar","year":"1996"},{"issue":"6","key":"10.1002\/14651858.CD013590.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ajh.22012","article-title":"Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management","volume":"86","author":"Nur","year":"2011","journal-title":"American Journal Hematology"},{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood.V41.5.653.653","article-title":"The sickle-unsickle cycle: a cause of cell fragmentation leading to permanently deformed cells","volume":"41","author":"Padilla","year":"1973","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0155|cit155","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013590.pub2-BIB0156|cit156","first-page":"1","article-title":"Nrf2, a master regulator of detoxification and also antioxidant","volume":"67","author":"Pall","year":"2015","journal-title":"Acta Physiologica Sinica"},{"issue":"2865","key":"10.1002\/14651858.CD013590.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia, a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science"},{"issue":"8","key":"10.1002\/14651858.CD013590.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ncomms1104","article-title":"Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis","volume":"1","author":"Piel","year":"2010","journal-title":"Nature Communications"},{"issue":"10","key":"10.1002\/14651858.CD013590.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions","volume":"7","author":"Piel","year":"2013","journal-title":"PLoS medicine"},{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1447S","DOI":"10.1093\/jn\/130.5.1447S","article-title":"The antioxidant properties of zinc","volume":"130","author":"Powell","year":"2000","journal-title":"Journal of Nutrition"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0161|cit161","unstructured":"Review Manager 5 (RevMan 5) Copenhagen: The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0162|cit162","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2023"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0163|cit163","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0164|cit164","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0002-9343(78)90053-0","article-title":"Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR","volume":"64","author":"Sherman","year":"1978","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.freeradbiomed.2013.08.181","article-title":"Oxidative stress in sickle cell disease: An overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies","volume":"65","author":"Silva","year":"2013","journal-title":"Free Radical Biology and Medicine"},{"issue":"19","key":"10.1002\/14651858.CD013590.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/bloodadvances.2017007211","article-title":"Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review","volume":"1","author":"Sins","year":"2017","journal-title":"Blood Advances"},{"issue":"5","key":"10.1002\/14651858.CD013590.pub2-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010858.pub3","article-title":"Vitamin D supplementation for sickle cell disease","author":"Soe","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Oct","key":"10.1002\/14651858.CD013590.pub2-BIB0169|cit169","first-page":"261","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2018","journal-title":"Annual Review of Pathology"},{"issue":"6","key":"10.1002\/14651858.CD013590.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009415.pub2","article-title":"Zinc supplements for treating thalassaemia and sickle cell disease","author":"Swe","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1534735416681639","article-title":"Potential contributions of antioxidants to cancer therapy:immunomodulation and radiosensitization","volume":"17","author":"Thyagarajan","year":"2018","journal-title":"Integrative Cancer Therapies"},{"issue":"2","key":"10.1002\/14651858.CD013590.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/antiox10020296","article-title":"Sickle cell disease: role of oxidative stress and antioxidant therapy","volume":"10","author":"Vona","year":"2021","journal-title":"Antioxidants"},{"issue":"10","key":"10.1002\/14651858.CD013590.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/antiox10101608","article-title":"The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications","volume":"10","author":"Wang","year":"2021","journal-title":"Antioxidants"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013590.pub2-BIB0175|cit175","unstructured":"World Health Organization (WHO) Sickle-Cell Disease: a strategy for the WHO African Region. Report of the Regional Director apps.who.int\/iris\/handle\/10665\/1682"},{"issue":"4","key":"10.1002\/14651858.CD013590.pub2-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013590","article-title":"Antioxidant supplementation for sickle cell disease","author":"Bolarinwa","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:17:42Z","timestamp":1755865062000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013590.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":176,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013590.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}